PMID- 38004612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231127
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 11
DP  - 2023 Nov 16
TI  - Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges.
LID - 10.3390/pharmaceutics15112635 [doi]
LID - 2635
AB  - Obesity has reached an epidemic proportion in the last thirty years, and it is 
      recognized as a major health issue in modern society now with the possibility of 
      serious social and economic consequences. By the year 2030, nearly 60% of the 
      global population may be obese or overweight, which emphasizes a need for novel 
      obesity treatments. Various traditional approaches, such as pharmacotherapy and 
      bariatric surgery, have been utilized in clinical settings to treat obesity. 
      However, these methods frequently show the possibility of side effects while 
      remaining ineffective. There is, therefore, an urgent need for alternative 
      obesity treatments with improved efficacy and specificity. Polymeric materials 
      and chemical strategies are employed in emerging drug delivery systems (DDSs) to 
      enhance therapy effectiveness and specificity by stabilizing and controlling the 
      release of active molecules such as natural ingredients. Designing DDSs is 
      currently a top priority research objective with an eye towards creating obesity 
      treatment approaches. In reality, the most recent trends in the literature 
      demonstrate that there are not enough in-depth reviews that emphasize the current 
      knowledge based on the creation and design of DDSs for obesity treatment. It is 
      also observed in the existing literature that a complex interplay of different 
      physical and chemical parameters must be considered carefully to determine the 
      effectiveness of the DDSs, including microneedles, for obesity treatment. 
      Additionally, it is observed that these properties depend on how the DDS is 
      synthesized. Although many studies are at the animal-study stage, the use of more 
      advanced DDS techniques would significantly enhance the development of safe and 
      efficient treatment approaches for obese people in the future. Considering these, 
      this review provides an overview of the current anti-obesity treatment approaches 
      as well as the conventional anti-obesity therapeutics. The article aims to 
      conduct an in-depth discussion on the current trends in obesity treatment 
      approaches. Filling in this knowledge gap will lead to a greater understanding of 
      the safest ways to manage obesity.
FAU - Ashour, Mohamed M
AU  - Ashour MM
AD  - School of Biotechnology, Badr University in Cairo, Badr City, Cairo 11829, Egypt.
FAU - Mabrouk, Mostafa
AU  - Mabrouk M
AUID- ORCID: 0000-0003-3330-6762
AD  - Refractories, Ceramics and Building Materials Department, National Research 
      Centre, 33 El Bohouth St., Dokki, Giza 12622, Egypt.
FAU - Aboelnasr, Mohamed A
AU  - Aboelnasr MA
AD  - Biophysics Branch, Faculty of Science, Al-Azhar University, Nasr City, Cairo 
      11884, Egypt.
FAU - Beherei, Hanan H
AU  - Beherei HH
AD  - Refractories, Ceramics and Building Materials Department, National Research 
      Centre, 33 El Bohouth St., Dokki, Giza 12622, Egypt.
FAU - Tohamy, Khairy M
AU  - Tohamy KM
AD  - Biophysics Branch, Faculty of Science, Al-Azhar University, Nasr City, Cairo 
      11884, Egypt.
FAU - Das, Diganta B
AU  - Das DB
AUID- ORCID: 0000-0001-9427-6582
AD  - Department of Chemical Engineering, Loughborough University, Loughborough 
      LE113TU, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231116
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10674714
OTO - NOTNLM
OT  - active molecules
OT  - anti-obesity drugs
OT  - microneedles
OT  - nanoparticles
OT  - natural ingredients
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/25 12:45
MHDA- 2023/11/25 12:46
PMCR- 2023/11/16
CRDT- 2023/11/25 01:23
PHST- 2023/10/15 00:00 [received]
PHST- 2023/11/13 00:00 [revised]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2023/11/25 12:46 [medline]
PHST- 2023/11/25 12:45 [pubmed]
PHST- 2023/11/25 01:23 [entrez]
PHST- 2023/11/16 00:00 [pmc-release]
AID - pharmaceutics15112635 [pii]
AID - pharmaceutics-15-02635 [pii]
AID - 10.3390/pharmaceutics15112635 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Nov 16;15(11):2635. doi: 10.3390/pharmaceutics15112635.